To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to
Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced
Migraine-like Attacks in Migraine Patients.